Russian General Staff: Nearly all low-orbit satellites within reach of US missile defenseMilitary & Defense March 28, 15:09
New Russian spacecraft designed for lunar missions to be run by fail-safe computerScience & Space March 28, 14:56
Putin hails Iran as Russia’s reliable and stable partnerRussian Politics & Diplomacy March 28, 14:17
Military expert warns US ABMs can detect any missile shield, even Russian onesMilitary & Defense March 28, 14:02
Scientists create modified fullerene capable of fighting HIVScience & Space March 28, 13:47
Kremlin notes Russian bank's contacts with Trump's son-in-law 'usual business practice'Business & Economy March 28, 13:28
Kremlin spokesman slams reports of his ‘secret visit’ to Lugansk as ‘fake news’Russian Politics & Diplomacy March 28, 13:19
Russia's Rosneft disappointed by EU Court’s decision on sanctions agains companyBusiness & Economy March 28, 13:10
Kremlin: Attacks on Russian business in Ukraine show country’s 'zero investor confidence'Business & Economy March 28, 13:05
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.